Water-soluble granulation for poultry drinking water places the narrowest control on residual moisture and particle size distribution because any fines fraction below 105 µm tends to form a transient concentration gradient in proportioner tanks, while oversized particles above 1.4 mm settle in dosing lines and reduce dose delivery at 20–30 mg/kg body weight. Production batches of 200 g/kg sulphachloropyridazine sodium oral granules are typically manufactured by high-shear wet granulation rather than dry blending because the sodium salt can exhibit a plate-like crystal habit with an angle of repose exceeding 40°, which promotes segregation of the active from lactose monohydrate at hopper discharge points. The batch formula comprises 20.0% w/w sulphachloropyridazine sodium, 67.0% w/w lactose monohydrate, 8.0% w/w sodium citrate dihydrate, 2.0% w/w citric acid anhydrous, 2.0% w/w povidone K30, and 1.0% w/w colloidal silicon dioxide. The granulating fluid is a 70:30 w/w mixture of purified water and ethanol containing povidone K30 at 20% w/w; it is sprayed at 1.2 kg/min into a 300 L high-shear mixer operating at an impeller speed of 250 rpm and a chopper speed of 1500 rpm, with wet massing continued for 4–6 minutes until the visual endpoint demonstrates hand-squeeze agglomeration without free liquid. The wet mass is passed through a 1.4 mm conical mill, dried in a fluid-bed dryer at an inlet air temperature of 55±5°C and a product temperature of 30–35°C until loss on drying reaches 1.5–2.0%, then dry-milled through 0.8 mm mesh and blended with colloidal silicon dioxide for 15 minutes in a 600 L bin blender at 15 rpm. The release specification for reconstituted granule dispersion in water at 25°C is not less than 90% of label claim within 15 minutes at 200 rpm paddle stirring; therefore, the product specification controls pH of the reconstituted solution at 8.0–9.5 because lower pH increases the proportion of poorly soluble free acid and leads to incomplete dosing. Relevant compliance standards for this non-sterile oral dosage form include Ph. Eur. 5.1.4 for microbiological quality, ICH Q3D(R2) for elemental impurities, VICH GL18 for residual ethanol, and 21 CFR 210/211 for finished pharmaceutical GMP. The terminal finished product is a 200 g/kg water-soluble granule filled into 1 kg or 5 kg polyester-polyethylene foil pouches under nitrogen-flushed conditions, intended for reconstitution in drinking water at a stock concentration of 100 g/L and then proportioner dilution to deliver 20–30 mg/kg body weight daily in broilers, layers, and turkeys.

Oral tablet compression of sulphachloropyridazine sodium in calf and swine unit dose forms

Compression of a 500 mg tablet requires lower lubricant concentration than capsule filling because prolonged mixing with magnesium stearate above 1.5% w/w imparts hydrophobic films around the soluble API and slows dissolution below the veterinary target of 80% release in 30 min in 0.1 M HCl. The core formula for a 500 mg sulphachloropyridazine sodium tablet with an 800 mg target core weight comprises 62.5% w/w API, 27.5% w/w microcrystalline cellulose PH-102, 5.0% w/w povidone K30, 3.0% w/w croscarmellose sodium, 1.0% w/w colloidal silicon dioxide, and 1.0% w/w magnesium stearate; a ready-mixed polyvinyl alcohol-based aqueous film coat at 2.0% w/w of core weight is applied to reduce dusting and mask the bitter aftertaste. The API and microcrystalline cellulose are dry-preblended in a 600 L high-shear granulator at 150 rpm for 5 minutes, after which purified water at 12–15% w/w of dry blend is sprayed at 0.8 kg/min while the impeller runs at 300 rpm and the chopper at 1500 rpm; wet massing lasts 4–6 minutes and the endpoint is defined by a light hand-press cake. The wet mass is milled through a 1.2 mm screen, dried at 60°C inlet air temperature to a loss on drying of 1.5–2.5%, and dry-milled through 0.8 mm mesh before final blending in a 600 L bin blender for 15 minutes at 15 rpm. Tableting on a 16-station rotary press at 25 rpm and 12–15 kN average compression force produces cores with 80–120 N hardness, not more than 1.0% friability, and 15 minutes maximum disintegration in 0.1 M HCl at 37°C. Release testing follows USP ⟨711⟩ with Apparatus 2 at 50 rpm because the high aqueous solubility of the sodium salt produces rapid erosion-driven dissolution rather than diffusion-limited release. Uniformity of dosage units follows USP ⟨905⟩, residual impurities follow ICH Q3B(R2), and manufacturing is conducted under 21 CFR 210/211; Ph. Eur. 2.9.5 uniformity of mass is used for European batches. Terminal finished pack types are 100-count HDPE bottles with silica-gel desiccant and child-resistant closures, labelled as veterinary prescription tablets of 500 mg for pre-ruminant calves and grower pigs.

What limits the holding time of a 200 mg/mL injectable solution before sterile filtration?

The limiting holding time for a 200 mg/mL sulphachloropyridazine sodium injection is governed by dissolved oxygen uptake, pH drift, and solution colour rather than by filter throughput. The aqueous solubility of the sodium salt at 25°C is sufficiently high to permit a 20.0% w/v active loading, but the free sulfonamide is weakly acidic; therefore, the solution is buffered to pH 8.5–9.5 to maintain the ionized state. A formulation per millilitre contains 200.0 mg sulphachloropyridazine sodium, 1.0 mg sodium metabisulfite, 0.1 mg disodium edetate, and 10.0 mg benzyl alcohol in water for injection. The solution is prepared in a jacketed 316L stainless steel vessel with bottom nitrogen sparging to reduce dissolved oxygen below 0.1 mg/L; the API is added at 400 rpm and 25°C, and the pH is adjusted with 1 M sodium hydroxide or 1 M hydrochloric acid after complete dissolution. The bulk solution is held at 20°C for no more than 8 hours before filtration because extended hold times lead to a 2–5% increase in absorbance at 420 nm and a pH drop of 0.2–0.4 units when headspace oxygen exceeds 0.3 mg/L. Filtration is performed through a 0.45 µm PVDF prefilter and then a 0.22 µm PVDF sterilizing filter with a differential pressure limit of 2.5 bar; filter integrity is tested by forward-flow bubble point pre- and post-filtration. The filtered solution is filled into 50 mL or 100 mL amber type II glass vials under nitrogen headspace and stoppered with bromobutyl closures. Terminal steam sterilisation is generally not the default for this sulfonamide formulation because published thermal degradation data are configuration-specific and limited; aseptic filtration is retained as the registered terminal sterilization strategy where 121°C moist-heat cycles have not been validated. The required quality standards include USP ⟨1⟩, USP ⟨788⟩ for subvisible particulates, USP ⟨790⟩ for visible particulates, ICH Q1A(R2) for stability, ICH Q3B(R2) for degradation products, 21 CFR 210/211, and EU GMP Annex 1 for sterile manufacture. The terminal finished product is a multidose injectable solution of 200 mg/mL for cattle, sheep, and pigs, filled in 100 mL amber vials with a shelf life not exceeding 24 months when stored below 25°C.

Encapsulation of the sodium salt into size 1 hard gelatin capsules for breeding stock is justified where water medication undershoots because hierarchical drinking behavior changes within a pen and individual sows, boars, or replacement gilts require separate dose capture. A 250 mg capsule is prepared with a fill weight of 320 mg using 78.1% w/w sulphachloropyridazine sodium, 17.9% w/w lactose monohydrate, 1.2% w/w croscarmellose sodium, 1.0% w/w colloidal silicon dioxide, 1.0% w/w talc, and 0.8% w/w magnesium stearate. The API is pre-sieved through a 0.5 mm screen and loaded into a low-shear V-blender with lactose, croscarmellose, and colloidal silicon dioxide; the blend is mixed for 15 minutes at 20 rpm, after which talc and magnesium stearate are added and mixing continues for an additional 3 minutes to limit lubricant over-coating. Capsule filling is conducted on an automatic tamping-pin filler with a 2.5 mm dosing disc, and fill weight is controlled at ±3% of target with 100% checkweighing. The formulation is deliberately dry-blended rather than wet-granulated because the capsule shell itself provides a barrier to moisture and the sodium salt has acceptable compaction under tamping-pin fill settings; this avoids the residual ethanol burden that would otherwise require VICH GL18 compliance at the capsule level. Dissolution testing follows USP ⟨711⟩ Apparatus 2 at 75 rpm in 900 mL of 0.1 M HCl, with a target of 80% released within 15 minutes; disintegration follows Ph. Eur. 2.9.1 in water at 37°C with a 15-minute limit for hard capsules. Quality requirements include USP ⟨2040⟩ for capsule weight variation, ICH Q3B(R2) for degradation products, and 21 CFR 210/211; microbial limits follow Ph. Eur. 5.1.4. Terminal finished product is a 250 mg hard gelatin capsule in 100-count HDPE bottles with desiccant, intended for oral administration to swine breeding stock.

When an Oral Solution Replaces Water-Soluble Powder in Lamb and Foal Dosing

A 100 mg/mL oral solution avoids the proportioner variability seen in water medication and allows dose correction to the nearest 0.5 kg of body weight in lambs and foals that are treated individually. The formulation uses 100.0 mg/mL sulphachloropyridazine sodium, 300.0 mg/mL sorbitol 70% non-crystallising, 1.0 mg/mL sodium metabisulfite, 0.1 mg/mL disodium edetate, and 0.02 M sodium citrate buffer, with purified water as the vehicle and pH adjusted to 8.5–9.5. The manufacturing sequence dissolves the API in 80% of the final volume of nitrogen-purged purified water at 25°C under 350 rpm stirring; after complete dissolution the sorbitol and buffer are added, pH is adjusted, and the solution is made to volume. The solution is filled into 100 mL or 1 L amber polyethylene terephthalate bottles with child-resistant closures under nitrogen headspace. Because this is a non-sterile oral liquid, the microbial quality specification follows Ph. Eur. 5.1.4 with a total aerobic microbial count limit of 10³ CFU/mL and total yeast/mould count of 10² CFU/mL. Stability follows ICH Q1A(R2) and residual solvents follow VICH GL18; the product is not terminally sterilized, and the sodium metabisulfite level is limited to 1.0 mg/mL to avoid exceeding the permitted daily sulfite exposure. Terminal finished product is an oral solution of 100 mg/mL in 100 mL and 1 L presentations, dispensed with a graduated dosing syringe for oral administration to lambs and foals.

Feed Premix Dilution Geometry and Carryover Control in Swine Rations

Production of a 10.0% w/w medicated feed premix demands geometric dilution rather than one-step blending because the active at 100 mg/g can segregate into dead zones at ribbon blender ends and produce carryover into later batches. The premix formula contains 10.0% w/w sulphachloropyridazine sodium, 88.0% w/w corn starch, 1.0% w/w mineral oil, and 1.0% w/w sodium aluminosilicate; mineral oil reduces dust and improves API adhesion to starch particles without altering the final drug release in complete feed. The API is first passed through a 0.5 mm screen and preblended with an equal weight of corn starch for 5 minutes in a 50 L low-shear mixer; this preblend is then expanded 1:5, then 1:25 with corn starch in a 500 kg ribbon blender at 20 rpm for 15 minutes per stage. Blend uniformity is verified by sampling 10 locations with a thief sampler and assaying via Ph. Eur. 2.2.29 HPLC; the coefficient of variation target is ≤5.0%. The final premix is packaged in 25 kg multi-wall paper bags with polyethylene liner and labelled for veterinary-directed incorporation into complete swine feed. Compliance requirements include ICH Q3D(R2) for elemental impurities, VICH GL1 for analytical method validation, VICH GL18 for residual methanol and ethanol if introduced through excipients, and 21 CFR 210/211 for drug premix manufacturing; carryover limits are set by the facility cleaning validation protocol. Terminal finished product type is a 10.0% w/w feed premix intermediate that is diluted in final feed under a veterinarian prescription, typically to achieve 20–30 mg/kg body weight daily in pigs.